Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175727 | 0.86 | TSHR (0.59) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL22355191 | 0.76 | ACHE (0.46) | KDM4EPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL23308872 | 0.76 | TSHR (0.59) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL1631053 | 0.76 | TSHR (0.65) | TSHRATMKDM4EPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL20502504 | 0.74 | TSHR (0.62) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL26894424 | 0.73 | TSHR (0.49) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL30746463 | 0.73 | TSHR (0.61) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL6320584 | 0.73 | KDM4E (0.61) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL21536752 | 0.72 | KDM4E (0.55) | TSHRATMKDM4EPOLBALDH1A1 | |
| SCHEMBL5632154 | 0.72 | TSHR (0.59) | TSHRATMKDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919884-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919884-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | TSHR 2598/4885ATM 1689/4885KDM4E 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.